NXGL

NexGel, Inc Common Stock

$0.59 -1.23%

Recent alerts on NXGL

All signals →

Insider trade Sale by Levy Adam R. (Chief Executive Officer)

Insider trade Purchase by Henry Scott Robert

Insider trade Purchase by Kieser Brian Joseph

Insider trade Purchase by Levy Adam R. (Chief Executive Officer)

News NEXGEL projects increased revenue in upcoming quarters - Investing.com

SEC filing NXGL Deficiency Letter: $1.00 Bid Price Below Nasdaq Minimum, 180-Day Cure Period Until Oct 19 2026, Potential Reverse Split

News NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition

SEC filing NXGL Acquires Celularity Degenerative Disease Segment for $5.5M, Triples Revenue to $35M, Launches BioNX Surgical, Immediate Accretion, 6 Reimbursed Products, 3 510(k)s Planned 2026-2028

News EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

News Kopin receives $2 million order for helmet-mounted display system from European defense contractor

Scanner Unusual volume (2.7x average)

News NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm

News NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm

News NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm

News NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm

News NX Investors Have Opportunity to Lead Quanex Building Products Corporation Securities Fraud Lawsuit with the Schall Law Firm

News NEXGEL (NXGL) Q3 2025 Earnings Call Transcript

Get push alerts for NXGL

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS